Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
Open Access
- 1 September 2024
- journal article
- review article
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (5) , e1990
Abstract
Polymeric nanoparticles (NPs), specifically those comprised of biodegradable and biocompatible polyesters, have been heralded as a game‐changing drug delivery platform. In fact, poly(α‐hydroxy acids) such as polylactide (PLA), poly(lactide‐co‐glycolide) (PLGA), and poly(ε‐caprolactone) (PCL) have been heavily researched in the past three decades as the material basis of polymeric NPs for drug delivery applications. As materials, these polymers have found success in resorbable sutures, biodegradable implants, and even monolithic, biodegradable platforms for sustained release of therapeutics (e.g., proteins and small molecules) and diagnostics. Few fields have gained more attention in drug delivery through polymeric NPs than cancer therapy. However, the clinical translational of polymeric nanomedicines for treating solid tumors has not been congruent with the fervor or funding in this particular field of research. Here, we attempt to provide a comprehensive snapshot of polyester NPs in the context of chemotherapeutic delivery. This includes a preliminary exploration of the polymeric nanomedicine in the cancer research space. We examine the various processes for producing polyester NPs, including methods for surface‐functionalization, and related challenges. After a detailed overview of the multiple factors involved with the delivery of NPs to solid tumors, the crosstalk between particle design and interactions with biological systems is discussed. Finally, we report state‐of‐the‐art approaches toward effective delivery of NPs to tumors, aiming at identifying new research areas and re‐evaluating the reasons why some research avenues have underdelivered. We hope our effort will contribute to a better understanding of the gap to fill and delineate the future research work needed to bring polyester‐based NPs closer to clinical application.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging TechnologiesKeywords
This publication has 526 references indexed in Scilit:
- Exploring and Analyzing the Systemic Delivery Barriers for NanoparticlesAdvanced Functional Materials, 2023
- Immune Cycle‐Based Strategies for Cancer ImmunotherapyAdvanced Functional Materials, 2021
- Strategies for Delivering Nanoparticles across Tumor Blood VesselsAdvanced Functional Materials, 2020
- Spray Drying2020
- Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2018
- Receptor‐Targeted Drug Delivery and the (Many) Problems We Know of: The Case of CD44 and Hyaluronic AcidAdvanced Biosystems, 2018
- Antitumor Platelet‐Mimicking Magnetic NanoparticlesAdvanced Functional Materials, 2017
- Remotely Controlled Red Blood Cell Carriers for Cancer Targeting and Near‐Infrared Light‐Triggered Drug Release in Combined Photothermal–ChemotherapyAdvanced Functional Materials, 2015
- Vitamin E and the Risk of Prostate CancerJAMA, 2011
- Freeze-drying of itraconazole-loaded nanosphere suspensions: a feasibility studyDrug Development Research, 1996